Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.
Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.